Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Valeant Pharmaceuticals International, Inc.
Index- P/E97.41 EPS (ttm)1.48 Insider Own2.30% Shs Outstand327.84M Perf Week4.34%
Market Cap47.26B Forward P/E14.43 EPS next Y9.99 Insider Trans7.16% Shs Float327.97M Perf Month1.04%
Income502.40M PEG3.64 EPS next Q2.49 Inst Own66.80% Short Float2.23% Perf Quarter24.33%
Sales8.05B P/S5.87 EPS this Y-610.50% Inst Trans21.71% Short Ratio2.80 Perf Half Y19.62%
Book/sh15.27 P/B9.44 EPS next Y20.80% ROA1.80% Target Price52.38 Perf Year28.71%
Cash/sh2.47 P/C58.43 EPS next 5Y26.74% ROE9.80% 52W Range106.00 - 153.10 Perf YTD22.79%
Dividend- P/FCF35.09 EPS past 5Y-33.00% ROI-0.10% 52W High-5.84% Beta0.87
Dividend %- Quick Ratio1.10 Sales past 5Y50.10% Gross Margin70.20% 52W Low36.00% ATR3.76
Employees17200 Current Ratio1.40 Sales Q/Q33.40% Oper. Margin29.00% RSI (14)59.22 Volatility3.10% 2.36%
OptionableYes Debt/Eq3.18 EPS Q/Q127.70% Profit Margin6.20% Rel Volume0.85 Prev Close146.06
ShortableYes LT Debt/Eq3.04 EarningsMay 08 BMO Payout0.00% Avg Volume2.62M Price144.16
Recom3.00 SMA201.02% SMA507.21% SMA20013.24% Volume2,214,107 Change-1.30%
Feb-28-14Reiterated UBS Buy $141 → $170
Feb-28-14Reiterated RBC Capital Mkts Outperform $151 → $158
Feb-27-14Reiterated Aegis Capital Buy $160 → $180
Jan-08-14Reiterated UBS Buy $125 → $141
Jan-08-14Reiterated Ladenburg Thalmann Buy $123 → $155
Jan-08-14Reiterated FBR Capital Outperform $130 → $153
Dec-03-13Reiterated UBS Buy $115 → $125
Nov-01-13Reiterated Ladenburg Thalmann Buy $127 → $123
Oct-30-13Initiated FBR Capital Outperform $130
Oct-07-13Reiterated CRT Capital Buy $110 → $130
Aug-08-13Reiterated UBS Buy $96 → $115
Aug-07-13Reiterated Aegis Capital Buy $135 → $140
Jul-02-13Reiterated RBC Capital Mkts Outperform $76 → $100
Jun-10-13Upgrade CRT Capital Hold → Buy $100
May-29-13Reiterated Ladenburg Thalmann Buy $84 → $124
May-29-13Reiterated Deutsche Bank Buy $82 → $103
May-03-13Reiterated Deutsche Bank Buy $80 → $82
Apr-04-13Reiterated UBS Buy $83 → $81
Apr-04-13Reiterated RBC Capital Mkts Outperform $80 → $76
Mar-21-13Reiterated Deutsche Bank Buy $77 → $83
Dec-22-14 06:23PM  Actavis, Valeant Largely Avoid Gilead's Hepatitis Dive at Investor's Business Daily
08:23AM  J.P. Morgan's 6 Top Biotech and Pharmaceuticals Stocks to Buy in 2015 at TheStreet
Dec-21-14 08:56AM  Corporate Review: A year to remember at Financial Times
Dec-18-14 07:10PM  Ackman Accused of Insider Trading in Allergan Shareholder Suit at Bloomberg
12:00PM  9 Big Stocks That Doubled in 2014 at 24/7 Wall St.
Dec-16-14 06:11PM  Great Stocks: Valeant Pharmaceuticals Near Buy Point at Investor's Business Daily
Dec-15-14 04:30PM  Valeant Pharmaceuticals To Hold Conference Call To Announce 2015 Financial Guidance PR Newswire
04:30PM  Valeant Pharmaceuticals To Hold Conference Call To Announce 2015 Financial Guidance CNW Group
Dec-13-14 12:01AM  NestlĂ© Chief Paul Bulcke Takes a Global View at
Dec-11-14 11:43AM  Shire Updates on Pipeline at Research & Development Day Zacks
Dec-10-14 01:39PM  JAZZ Pharmaceuticals Slips After Dosing Issue on JZP-386 Zacks
09:18AM  Herb Greenberg: What's Next for Valeant After Its Botched Bid for Allergan at TheStreet
Dec-09-14 03:02PM  Zoetis Inc. Spikes Briefly On Remarks From Sanofi CEO Benzinga
01:50PM  UCB Reports Phase III Data on Epilepsy Drug, To File in 2015 Zacks
01:38PM  Where Could ValueAct Capital's New $1.5 Billion Go? Benzinga
11:55AM  Stock Market Today: Wall Street Drops; Conn's Down 40% at Investor's Business Daily
08:41AM  Valeant puts dealmaking on hold to focus on the bottom line at Fortune
07:52AM  Will Valeant Pharmaceuticals (VRX) Stock be Helped Today by New Strategy? at TheStreet
06:56AM  December 9 Premarket Briefing: 10 Things You Should Know TheStreet
Dec-08-14 06:18PM  Two Gauges That Point To Fund Buying In A Stock at Investor's Business Daily
02:30PM  Novartis (NVS) Presents Additional Data on Leukemia Drug Zacks
Dec-05-14 06:54PM  Inside The IBD 50: Challenging Time For Growth Stocks at Investor's Business Daily
05:50PM  Roche to Acquire California-based Ariosa Diagnostics Zacks
12:48PM  Activist Investors Torn on Private Equity Partnerships at TheStreet
09:17AM  Goldman's Parker Calls Allergan Pursuit a 'One-time Opportunity' at TheStreet
Dec-04-14 07:54PM  Can Health Care Sector's Fund Romp Continue? at Investor's Business Daily
04:17PM  Why the Allergan Situation Could be Unique in Dealmaking This Year at TheStreet
Dec-03-14 02:30PM  Avanir to be acquired by Otsuka for $3.5 Billion, Shares Up Zacks
02:23PM  Shareholder Value: The World's Dumbest Idea? at
08:50AM  Jazz Pharmaceuticals (JAZZ) Starts Late-Stage Study on Xyrem Zacks
08:42AM  Valeant (VRX) Stock: Moving Average Crossover Alert Zacks
Dec-02-14 04:00PM  Novartis' Multiple Sclerosis Drug Gilenya Fails Phase III Study Zacks
01:29PM  Exelixis Shares Down on COMET-2 Study Results on Cabozantinib Zacks
05:00AM  Unpatriotic Loophole Targeted by Obama Costs Taxpayers $2 Billion Bloomberg
05:00AM  Unpatriotic Loophole Targeted by Obama Costs $2 Billion at Bloomberg
Dec-01-14 06:58PM  Some Big Cap 20 Names Holding Up In Monday's Sell-Off at Investor's Business Daily
05:30PM  Valeant's Onexton Gel Gets FDA Approval for Acne Zacks
11:36AM  Jim Cramer on the Stock Market: Here Are 12 Sectors to Bet On at TheStreet
Nov-28-14 05:10PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
05:00PM  Valeant Announces Redemption of US$445.0 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018 PR Newswire
05:00PM  Valeant Announces Redemption of US$445.0 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018 CNW Group
10:30AM  ETF Spotlight: Active Large-Cap Growth Strategy ETF Trends
10:10AM  Valeant Pharmaceuticals International (VRX) Showing Signs Of Being A Momo Momentum Stock at TheStreet
04:44AM  Bio Blast Pharma (ORPN) in Focus: Stock Moves Up 26.6% Zacks
Nov-27-14 12:29PM  Non-Gaap measures: we're not savages at Financial Times
Nov-25-14 06:35PM  5 Ways CEOs Handle Activist Investors at The Wall Street Journal
12:22PM  Today's Stocks Driving Success For The Drugs Industry at TheStreet
08:00AM  JANA Partners adds a new position in Valeant Pharmaceuticals Market Realist
08:00AM  Valeant Pharmaceuticals Announces FDA Approval Of ONEXTON Gel For The Treatment Of Acne Vulgaris PR Newswire
08:00AM  Valeant Pharmaceuticals Announces FDA Approval Of ONEXTON Gel For The Treatment Of Acne Vulgaris CNW Group
07:52AM  Ariad Pharmaceuticals (ARIA) Jumps: Stock Gains 9.7% Zacks
Nov-24-14 12:00PM  JANA Partners opens a stake in Amgen Market Realist
11:33AM  Notable option trades in equities optionMONSTER
11:06AM  Activis, Allergan CEOs Discuss Details of Purchase at Bloomberg
Nov-21-14 03:30PM  Highlights of activist fund JANA Partners 3Q 13F Market Realist
12:25PM  Midday movers: Intel, Toyota, Petrobras & more at CNBC
09:19AM  What a week: Botox haze, merger Monday and The Tanned One at MarketWatch
04:11AM  After losing out over Allergan, Valeant announces $2 billion buyback at Fortune
Nov-20-14 03:35PM  Shire to Relocate Employees Under One Shire Program Zacks
03:34PM  Synergy Pharmaceuticals Drug Fares Well in Phase II Study Zacks
12:29PM  Midday Movers: Dillard's, GoPro, Apple & more at CNBC
11:38AM  Valeant Pharmaceuticals Announces New $2 Billion Securities Repurchase Program PR Newswire
11:38AM  Valeant Pharmaceuticals Announces New $2 Billion Securities Repurchase Program CNW Group
Nov-19-14 06:14PM  Valeant Rises After Allergan Snub; Zeltiq In Buy Area at Investor's Business Daily
04:45PM  Zoetis Provides 2015 Earnings Guidance Below Estimates Zacks
11:36AM  Goldman Hits Motherlode in Deal Making at MarketWatch
Nov-18-14 04:20PM  Zoetis to Buy Abbott's Animal Health Assets for $255 Million Zacks
04:17PM  Stocks Hit New Milestones; BitAuto Rebounds at Investor's Business Daily
03:15PM  Zoetis 2015 Guidance Misses As Buyout Theories Abound at Investor's Business Daily
03:02PM  Actavis: One Day Later, Investors Really Like Allergan Acquisition at
02:38PM  Stock Movers: Why 4 Big Drug Stocks Are Rising Today at Investor's Business Daily
01:35PM  Profit At Zoetis Will Miss Wall Street's Expectations Next Year Business Insider
01:33PM  Stocks Hold Near Fresh Milestones; Actavis Hits New High at Investor's Business Daily
01:10PM  Ackman Pledges Support For Actavis Bid On Allergan Benzinga
12:30PM  Actavis shares outpace buyout targets gains at MarketWatch
12:20PM  Actavis Strikes $66 Billion Deal for Botox Maker Allergan Zacks
11:06AM  Four IBD Top 50 Stocks on the Way Up at Forbes
10:56AM  Is Bill Ackman Back? Benzinga
10:55AM  Cramer: Zoetis Defends Against Takeover; GoPro Is Going Higher at TheStreet
10:35AM  Stocks Climb In Mixed Trade; First Wind Deal Lifts SunEdison at Investor's Business Daily
08:00AM  Valeant Pharmaceuticals And IDEAL IMPLANT Announce FDA And Health Canada Approval To Market Ideal Implant For Cosmetic Breast Augmentation PR Newswire
08:00AM  Valeant Pharmaceuticals And IDEAL IMPLANT Announce FDA And Health Canada Approval To Market Ideal Implant For Cosmetic Breast Augmentation CNW Group
07:52AM  Zoetis unveils $500 million buyback plan at MarketWatch
05:29AM  Hedge funds ditch Apple for AbbVie and Alibaba at CNBC
12:40AM  Actavis Agrees to Buy Botox Maker Allergan at The Wall Street Journal
Nov-17-14 08:00PM  [$$] Actavis to Buy Allergan for $66 Billion at The Wall Street Journal
06:45PM  Here Are Some Big Caps Poised To Make Gains at Investor's Business Daily
06:27PM  Five Ethical Drugmakers Keep Leadership Positions at Investor's Business Daily
06:07PM  Cramer: The lucrative journey of Allergan at CNBC
05:31PM  Actavis Will Acquire Botox Firm Allergan For Over $66 Billion Investor's Business Daily
05:16PM  Allergan Sides With More Aggressive Dealmaker By Picking Actavis Over Valeant at Forbes
05:01PM  Actavis to spend $66 billion on Allergan AP
04:38PM  Allergan CEO hands Botox maker to lawyer instead of consultant at Fortune
04:30PM  Stocks End Mixed; Japan, M&A in Focus Morningstar
04:05PM  Allergan sees off Valeant by sealing $66bn deal with Actavis at Financial Times
03:18PM  Ackman's win-win CNBC
03:13PM  Stocks Mixed In Afternoon; Allergan Jumps To New High at Investor's Business Daily
02:31PM  Bill Ackman Wins 2014 at Forbes
02:26PM  Ackman Reaps $2.5 Billion From Allergan Even in Loss to Actavis at Bloomberg
01:31PM  Bill Ackman Wins 2014 Forbes
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Its pharmaceutical products include Solodyn, an oral antibiotic that treats red and pus-filled pimples, as well as Ziana, Acanya, and Atralin; Wellbutrin XL, a formulation used for the treatment of major depressive disorder in adults; Xenazine for the treatment of chorea; Zovirax Cream for herpes labialis; Zovirax ointment for initial genital herpes; The Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; and Prolensa, a non-steroidal anti-inflammatory ophthalmic solution. The company also provides OTC products, such as PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus, a sterile that is used to lubricate and rewet soft contact lenses; Ocuvite, a lutein eye vitamin and mineral supplement; Artelac, an eye drops to treat dry eyes; and CeraVe products for skin. In addition, it offers device products, including SofLens daily disposable contact lenses; Restylane, an injectable implant dermal fillers; PureVision, a contact lens; Dysport, an injection neurotoxin; ophthalmic surgical products, such as Akreos and Crystalens; surgical equipment comprising the VICTUS femtosecond laser and the Stellaris PC, a vitreoretinal and cataract surgery system; and medical device systems for aesthetic applications. Further, it provides generic products comprising Retin-A Micro, a tretinoin gel; tobramycin and dexamethasone ophthalmic suspensions for steroid responsive inflammatory ocular conditions; and latanoprost to treat glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Farmer Ronald HaroldDirectorDec 12Buy160.4850080,24033,004Dec 16 02:59 PM
UBBEN JEFFREY WDirectorDec 10Buy139.2950,0006,964,50018,030,936Dec 11 06:59 PM
UBBEN JEFFREY WDirectorDec 09Buy140.25200,00028,050,00017,980,936Dec 11 06:59 PM
STEVENSON KATHARINE BERGHUISDirectorDec 03Buy145.731,500218,59523,098Dec 03 04:48 PM
Farmer Ronald HaroldDirectorNov 24Buy163.951,000163,95032,504Dec 01 05:25 PM
UBBEN JEFFREY WDirectorNov 24Buy142.25210,00029,872,50017,780,936Nov 26 04:11 PM
Stolz Brian M.EVP, Administration and CHCOOct 10Option Exercise0.003,675084,791Oct 14 02:51 PM
Schiller Howard BradleyEVP and CFOOct 03Option Exercise0.0022,5000285,500Oct 07 04:19 PM
Stolz Brian M.EVP, Administration and CHCOSep 30Option Exercise0.0023,030093,064Oct 02 03:52 PM
Stolz Brian M.EVP, CHCO and AdministrationAug 06Option Exercise0.0018,111079,431Aug 07 03:53 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Jun 23Option Exercise6.4510,20365,80934,202Jun 24 04:37 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Jun 23Sale121.7010,2031,241,67623,999Jun 24 04:37 PM
Mirovsky PavelPresident of Valeant EuropeJun 02Sale131.2510,0001,312,4860Jun 04 03:19 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.May 13Option Exercise6.4510,00064,50033,999May 14 04:29 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.May 13Sale130.0810,0001,300,83623,999May 14 04:29 PM
Provencio Norma AnnDirectorApr 01Sale132.185,000660,886137,495Apr 02 04:55 PM
Kornwasser LaizerEVP, Company Group ChairmanMar 21Buy134.972,481334,85953,582Mar 25 01:06 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Mar 17Option Exercise6.455,00032,25028,999Mar 19 04:33 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Mar 17Sale141.725,000708,60023,999Mar 19 04:33 PM
Weldon RyanEVP, Company Group ChairmanFeb 11Option Exercise0.0011,0000103,823Feb 12 04:43 PM
Stolz Brian M.EVP, Administration & CHCOFeb 11Option Exercise0.0014,700069,783Feb 12 04:08 PM
Schiller Howard BradleyEVP, CFOFeb 11Option Exercise0.0090,0000312,704Feb 12 03:51 PM
Kornwasser LaizerEVP, Company Group ChairmanFeb 11Option Exercise0.0045,000073,390Feb 12 03:34 PM
Provencio Norma AnnDirectorFeb 03Sale136.235,000681,158147,206Feb 04 06:15 PM
Weldon RyanEVP, Company Group ChairmanJan 24Option Exercise0.0019,0000101,539Jan 28 05:09 PM
Mirovsky PavelPresident of Valeant EuropeJan 24Option Exercise0.0010,000010,000Jan 28 05:00 PM
Kornwasser LaizerEVP, Company Group ChairmanJan 24Buy132.152,536335,12828,390Jan 28 04:51 PM
Stolz Brian M.EVP, Administration and CHCOJan 20Option Exercise0.0045,000077,939Jan 22 04:55 PM